NIPPON INDIA PHARMA FUND

Sectoral / ThematicEquity SEBI-regulated

NAV (Direct-Growth)

₹623.4794

As of 1 Jul 2026 · AMFI

AUM

₹8.6K Cr

Expense ratio

0.79%

1Y returns

+8.23%

cat 12.11%

3Y CAGR

+21.63%

cat 22.73%

5Y CAGR

+13.62%

cat 13.72%

Std deviation 3Y

+15.23%

cat 16.65%

In plain English

NIPPON INDIA PHARMA FUND is a Sectoral / Thematic scheme from Nippon India. The portfolio is ~98% in equities. Long-run track record: about 13.6% CAGR over 5 years. Volatility is typical for equity — 20–30 % drawdowns happen during market stress. Worst historical drawdown: -24% in May 2017, recovered in 15 months. Wrong fit if you need this money in less than 7 years.

Auto-generated from holdings, returns and risk data. No paid placement, no copy-pasted boilerplate.

NAV history

NAV (Direct-Growth)

₹623.4794

Last 1Y

+8.23%

Jul 25Min ₹539.27 · Max ₹626.14 · 245 ptsJul 26

Drawdown stories

The crashes you should know about — and how long the fund took to recover.

May 2017

-24.0%

Peak ₹160.57 on 30 Oct 2015 → trough ₹122.00 on 29 May 2017 (19 months down).

Recovered in 15 months· 17 Aug 2018

Mar 2020

-21.2%

Peak ₹175.55 on 19 Feb 2020 → trough ₹138.36 on 23 Mar 2020 (1 months down).

Recovered in 1 months· 9 Apr 2020

Jun 2022

-19.5%

Peak ₹341.49 on 15 Sept 2021 → trough ₹274.97 on 17 Jun 2022 (9 months down).

Recovered in 13 months· 28 Jun 2023

Oct 2019

-17.4%

Peak ₹173.80 on 7 Sept 2018 → trough ₹143.56 on 7 Oct 2019 (13 months down).

Recovered in 5 months· 19 Feb 2020

Computed from the full NAV history. We show drawdowns deeper than 10%, sorted by depth.

Honesty score

A 1–5 grade on the dimensions other sites won't surface — expense bloat, AUM bloat, concentration, mandate compliance.

Honesty score

4 / 5

Solid scheme on the dimensions we check. No red flags.

Expense ratio
0.79% — typical for category.
AUM size
₹8.6K Cr.
Sector concentration
Top 3 sectors = 98.7% — heavy concentration risk.

Computed from expense ratio, AUM, sector concentration and SEBI mandate compliance. No paid review.

Performance

Returns for various periods, with category average and peer rank.

Period	Returns	Category avg	Rank
1W	+2.88%	+0.29%	10/ 19
1M	+4.54%	+3.93%	16/ 19
3M	+6.71%	+5.61%	14/ 19
6M	+9.48%	+12.10%	15/ 19
YTD	+9.42%	+11.97%	15/ 19
1Y	+8.23%	+12.11%	15/ 18
2Y	+10.84%	+12.10%	10/ 15
3Y	+21.63%	+22.73%	10/ 12
5Y	+13.62%	+13.72%	9/ 11
7Y	+19.93%	+19.14%	8/ 10
10Y	+15.47%	+13.62%	2/ 5

Portfolio composition

Asset allocation

Equity97.92%
Cash2.08%

By market cap

Large cap40.18%
Mid cap27.34%
Small cap30.05%
Others2.43%

Concentration

Holdings

Avg market cap

₹63.9K Cr

Top 10 stocks

59.53%

Top 5 stocks

40.92%

Top 3 sectors

98.68%

Top holdings

Top 15 positions by weight, latest disclosure.

#InstrumentSectorWeight

1
Sun Pharmaceuticals Industries Ltd
—13.92%
1
Sun Pharmaceuticals Industries Ltd
—13.85%
2
Lupin Ltd
—8.45%
2
Lupin Ltd
—7.95%
3
Dr Reddy's Laboratories Ltd
—7.04%
4
Divi's Laboratories Ltd
—6.61%
3
Divi's Laboratories Ltd
—6.41%
4
Dr Reddy's Laboratories Ltd
—5.96%
5
Cipla Ltd
—5.47%
5
Cipla Ltd
—5.42%
6
Apollo Hospitals Enterprise Ltd
—5.15%
6
Apollo Hospitals Enterprise Ltd
—5.01%
7
Medplus Health Services Ltd
—3.86%
7
Medplus Health Services Ltd
—3.78%
8
Vijaya Diagnostic Centre Ltd
—3.36%

Fundamentals (vs category)

Portfolio-weighted ratios, compared with the category average.

MetricFundCategory avgDiff

P/E ratio36.7140.99-4.28
P/B ratio5.415.77-0.36
Price / Sales4.995.66-0.67
Price / Cash Flow26.7230.34-3.62
Dividend yield0.80%0.63%+0.17
Return on equity (ROE)17.53%16.53%+1.00

Risk metrics

Standard deviation, Sharpe, Sortino, Beta — all vs category average.

Metric1Y3Y5YCat 1YCat 3YCat 5Y

Standard deviation
Volatility — lower means steadier returns.
15.7915.2314.7914.5316.6515.39
Sharpe ratio
Risk-adjusted return — higher is better.
0.250.970.570.401.030.57
Sortino ratio
Like Sharpe but only counts downside volatility.
0.381.660.890.671.840.92
Beta
1 = moves with the market. <1 = less volatile.
0.880.890.910.930.950.94

Peers in Sectoral / Thematic

Other schemes in the same SEBI category, ranked by AUM.

Peer fundAUM1Y3Y CAGRExpense

Peers in same SEBI category, ranked by AUM. Compare any →

Available plans & options

PlanOptionFull nameISIN

DirectGrowthNippon India Pharma Fund - Direct Plan Growth Plan - Bonus OptionINF204K01I27
DirectIDCW ReinvestmentNIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW OptionINF204K01I35
RegularIDCW ReinvestmentNIPPON INDIA PHARMA FUND - IDCW OptionINF204K01935

NEW

See your SIP through Indian market history

Pick a fund and a start year — get a 60-second cinematic replay of every crash, boom, and headline with your money in it. Real NAV data, no “assumed 12%” lies.

Try Wealth Time Machine

AI · Free

Find what's really inside your funds

Upload your CAS PDF — get instant stock concentration, hidden fund overlap, sector risk, and 3 specific actions, written by AI in plain English.

Run Portfolio X-Ray